A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL
and NHL who have failed or are intolerant to standard of care.